Diansheng Zhong

机构：Tianjin Medical University General Hospital

发表论文 188 篇 · 总被引 3259 次 · h-index 28

代表论文

• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial (2025 · Nature Medicine · 被引 19)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial (2024 · Med · 被引 16)
• CBX4 plays a bidirectional role in transcriptional regulation and lung adenocarcinoma progression (2024 · Cell Death and Disease · 被引 9)
• Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades (2025 · Journal of Cancer · 被引 8)
• A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer (2024 · Med · 被引 8)